Akorn Propriété institutionnelle
Quel est le Propriété institutionnelle de Akorn?
Le Propriété institutionnelle de Akorn, Inc. est 75.93%
Quelle est la définition de Propriété institutionnelle?
La propriété institutionnelle est le montant des actions disponibles d'une société détenues par des fonds mutuels ou des fonds de pension, des compagnies d'assurance, des sociétés d'investissement, des fonds de dotation ou d'autres grandes entités qui gèrent des fonds pour le compte de tiers.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Propriété institutionnelle des entreprises dans Health Care secteur sur OTC par rapport à Akorn
Que fait Akorn?
Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Entreprises avec propriété institutionnelle similaire à Akorn
- Glenveagh Properties Plc a Propriété institutionnelle de 75.89%
- Golar LNG a Propriété institutionnelle de 75.89%
- Golar Lng a Propriété institutionnelle de 75.89%
- Ted Baker Plc a Propriété institutionnelle de 75.89%
- Penn Virginia a Propriété institutionnelle de 75.90%
- Squarespace a Propriété institutionnelle de 75.92%
- Akorn a Propriété institutionnelle de 75.93%
- Baring Emerging Europe Plc a Propriété institutionnelle de 75.93%
- NovoCure Ltd a Propriété institutionnelle de 75.94%
- Custom Truck One Source Inc a Propriété institutionnelle de 75.94%
- Summit Securities a Propriété institutionnelle de 75.95%
- Pets At Home Plc a Propriété institutionnelle de 75.96%
- MetLife a Propriété institutionnelle de 75.98%